RXRen-Ai Xu

Ren-Ai Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ren-Ai Xu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Dapeng Dai

    Department of Basic Innovation Research, Beijing Hospital, National Center or Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Beijing Key Laboratory of Aging Mechanism and Intervention Research on Aging-Related Diseases; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    1 shared publication
  • Fu-Chen Xie

    Department of Urinary Surgery

    1 shared publication
  • Guo-Xin Hu

    School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China

    1 shared publication
  • Jian-Ping Cai

    The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

    1 shared publication
  • Lingjing Yuan

    School of Pharmacy (X.H., T.L., L.Y., Q.Z., Y.L., G.H.) and First Affiliated Hospital (R.X.), Wenzhou Medical University, Wenzhou, Zhejiang, China; and Key Laboratory of Geriatrics, Beijing Hospital, Beijing, China (D.D., J.C.)

    1 shared publication
  • Qiang Zhang

    Department of Clinical Laboratory

    1 shared publication

Latest Publications

  • Open Access

    Development of a Prognostic Five-Gene Signature with Radiotherapy Guidance Significance for Diffuse Lower-Grade Glioma Patients Based on Large-Scale Sequencing Data

    by Qiang Zhang, Shun-Bin Luo, Fu-Chen Xie, Xiao-Jun Liu, Ren-Ai Xu

    Background: Diffuse lower-grade gliomas (LGGs) are infiltrative and heterogeneous neoplasms. Gene signature including multiple protein coding genes (PCGs) is widely used as tumor markers. This study aimed to construct a multi-PCG signature to predict survival for LGG patients.Methods: LGG data including PCG expression profiles and clinical information were downloaded from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA). Survival analysis, receiver operating characteristic (ROC) analysis and random survival forest algorithm (RSFVH) were used to identify the prognostic PCG signature.Results: From the training (n = 524) and test (n = 431) datasets, a five-PCG signature which can classify LGG patients into low- or high-risk group with significantly different overall survival (Log Rank P < 0.001) was screened out and validated. In terms of prognosis predictive performance, the five-PCG signature is stronger than other clinical variables and IDH mutation status. Moreover, the five-PCG signature could further divide radiotherapy patients into two different risk groups. GO and KEGG analysis found PCGs in the prognostic five-PCG signature were mainly enriched in cell cycle, apoptosis, DNA replication pathways.Conclusions: The new five-PCG signature is a reliable prognostic marker with radiotherapy guidance significance for LGG patients and has a good prospect in clinical application.

  • Open Access

    Evaluation of 24 CYP2D6 Variants on the Metabolism of Nebivolol In Vitro

    by Xiaoxia Hu, Tian Lan, Dapeng Dai, Ren-Ai Xu, Lingjing Yuan, Quan Zhou, Yunxuan Li, Jianping Cai, Guoxin Hu

    CYP2D6 is an important cytochrome P450 (P450) enzyme that metabolizes approximately 25% of therapeutic drugs. Its genetic polymorphisms may significantly influence the pharmacokinetics and pharmacodynamics of clinically used drugs. Studying the effects of CYP2D6 on drug metabolism can help reduce adverse drug reactions and therapeutic failure to some extent. This study aimed to investigate the role of CYP2D6 in nebivolol metabolism by evaluating the effect of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. CYP2D6 variants expressed by insect cell systems were incubated with 0.1–80 μM nebivolol for 30 minutes at 37°C and the reaction was terminated by cooling to −80°C immediately. An ultra-performance liquid chromatography–tandem mass spectrometry system was used to analyze nebivolol and its metabolite 4-hydroxy nebivolol. Compared with CYP2D6.1, the intrinsic clearance values of most variants were significantly altered, and most of these variants exhibited either reduced Vmax and/or increased Km values. Variant R440C showed much higher intrinsic clearance than the wild type (219.08%). Five variants (CYP2D6.88, CYP2D6.89, R344Q, V342M, and D336N) exhibited no difference from the wild type. CYP2D6.92 and CYP2D6.96 displayed weak or no activity, whereas the intrinsic clearance values of the remaining 16 variants were significantly reduced to various degrees (ranging from 4.07% to 71%). As the first report of 24 CYP2D6 alleles for nebivolol metabolism, these results are valuable to interpreting in vivo studies and may also serve as a reference for rational clinical administration.